Prof. Dan Cao, West China Hospital, Sichuan University, China
Prof. Stephen L. Chan, The Chinese University of Hong Kong, China
Prof. Lorenza Rimassa, Humanitas University and IRCCS Humanitas Research Hospital, Italy
Prof. Huanji Xu, West China Hospital, Sichuan University, China
Prof. Cao, Prof. Chan, Prof. Rimassa and Prof. Xu discussed key treatment strategies in hepatocellular carcinoma (HCC), including how to differentiate between patients more suitable for dual immunotherapy versus atezolizumab plus bevacizumab in the first-line setting, as well as how to individualize TACE-based combination therapy according to tumor burden and liver function. They also explored the evolving role of conversion therapy in downstaging HCC and highlighted the major unresolved questions surrounding the integration of systemic treatment and surgery.